SG11201900654QA - Anti-kras-g12d t cell receptors - Google Patents
Anti-kras-g12d t cell receptorsInfo
- Publication number
- SG11201900654QA SG11201900654QA SG11201900654QA SG11201900654QA SG11201900654QA SG 11201900654Q A SG11201900654Q A SG 11201900654QA SG 11201900654Q A SG11201900654Q A SG 11201900654QA SG 11201900654Q A SG11201900654Q A SG 11201900654QA SG 11201900654Q A SG11201900654Q A SG 11201900654QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- maryland
- avenue
- pct
- kras
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 February 2018 (08.02.2018) WIP0 I PCT olimion °nolo omolom Kill Bo 11111°1 Hs (10) International Publication Number WO 2018/026691 Al (51) International Patent Classification: C07K 14/725 (2006.01) C07K 14/82 (2006.01) (21) International Application Number: PCT/US2017/044615 (22) International Filing Date: 31 July 2017 (31.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/369,883 02 August 2016 (02.08.2016) US (71) Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DE- PARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Office of Technology Transfer, National Insti- tutes of Health, 6011 Executive Boulevard, Suite 325, MSC 7660, Bethesda, Maryland 20892-7660 (US). (72) Inventors: TRAN, Eric; 1650 NE 32nd Avenue, Apt 312, Portland, Oregon 97232 (US). LU, Yong-Chen; 1620 East Jefferson, Apt 111, Rockville, Maryland 20852 (US). PASETTO, Anna; 225 Rollins Avenue, Rockville, Mary- land 20852 (US). ROBBINS, Paul F.; 7907 Glendale Road, Chevy Chase, Maryland 20815 (US). ROSEN- BERG, Steven A.; 10104 Iron Gate Road, Potomac, Mary- land 20854 (US). ZHENG, Zhili; 301 Alderwood Drive, Gaithersburg, Maryland 20878 (US). (74) Agent: LAWLEY, Stephanie M. et al.; Leydig, Voit & Mayer, Two Prudential Plaza, Suite 4900, 180 North Stet- son Avenue, Chicago, Illinois 60601 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: ANTI-KRAS-G12D T CELL RECEPTORS (57) : Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369883P | 2016-08-02 | 2016-08-02 | |
| PCT/US2017/044615 WO2018026691A1 (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900654QA true SG11201900654QA (en) | 2019-02-27 |
Family
ID=59564253
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900654QA SG11201900654QA (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
| SG10201913959WA SG10201913959WA (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913959WA SG10201913959WA (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US10611816B2 (en) |
| EP (2) | EP3494133B1 (en) |
| JP (4) | JP6993402B2 (en) |
| KR (1) | KR102527052B1 (en) |
| CN (2) | CN118063591A (en) |
| AU (2) | AU2017306038B2 (en) |
| CA (1) | CA3032870A1 (en) |
| DK (1) | DK3494133T3 (en) |
| ES (1) | ES2928051T3 (en) |
| HR (1) | HRP20221183T1 (en) |
| HU (1) | HUE060121T2 (en) |
| IL (2) | IL264425B2 (en) |
| LT (1) | LT3494133T (en) |
| PL (1) | PL3494133T3 (en) |
| PT (1) | PT3494133T (en) |
| RS (1) | RS63615B1 (en) |
| SG (2) | SG11201900654QA (en) |
| SI (1) | SI3494133T1 (en) |
| SM (1) | SMT202200379T1 (en) |
| WO (1) | WO2018026691A1 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL264425B2 (en) * | 2016-08-02 | 2023-09-01 | Us Secretary Department Of Health And Human Services | Anti-kras-g12d t cell receptors |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| CR20240019A (en) | 2017-09-20 | 2024-02-15 | Us Health | HLA CLASS II RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS (Divisional file 2020-0150) |
| EP4269595A3 (en) | 2017-10-05 | 2023-12-06 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Methods for selectively expanding cells expressing a tcr with a murine constant region |
| MX2020014243A (en) | 2018-06-19 | 2021-05-12 | Biontech Us Inc | NEOANTIGENS AND THEIR USES. |
| SG11202108039QA (en) * | 2019-01-25 | 2021-08-30 | Univ Pennsylvania | Compositions and methods for targeting mutant ras |
| WO2020172332A1 (en) * | 2019-02-20 | 2020-08-27 | Fred Hutchinson Cancer Research Center | Binding proteins specific for ras neoantigens and uses thereof |
| CN110172089B (en) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | KRAS mutant multi-antigen combination, targeting KRAS mutant tumor CTL and application thereof |
| CN112110995A (en) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | Tumor neoantigen polypeptide and application thereof |
| CN112760290A (en) * | 2019-10-21 | 2021-05-07 | 郑州大学 | Stem cells carrying mutated tumor driver genes and uses thereof |
| CN112759641B (en) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | High-affinity TCR for recognizing Kras G12V |
| CA3160468A1 (en) * | 2019-11-05 | 2021-05-14 | Board Of Regents, The University Of Texas System | Hla restricted hormad1 t cell receptors and uses thereof |
| AU2020408017A1 (en) | 2019-12-20 | 2022-07-14 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| CN116034113A (en) * | 2019-12-30 | 2023-04-28 | 华夏英泰（北京）生物技术有限公司 | A kind of enhanced T cell receptor STAR and its application |
| AU2021310213A1 (en) * | 2020-07-13 | 2023-03-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA class II–restricted DRB T cell receptors against ras with g12d mutation |
| AU2021351710A1 (en) * | 2020-10-02 | 2023-06-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| WO2022109220A1 (en) * | 2020-11-20 | 2022-05-27 | Think Therapeutics, Inc. | Compositions and methods for optimized peptide vaccines |
| AU2021388167A1 (en) * | 2020-11-25 | 2023-07-06 | Geneius Biotechnology, Inc. | Antigen specific t cells and methods of making and using same |
| US20240175047A1 (en) | 2021-02-25 | 2024-05-30 | Alaunos Therapeutics, Inc. | Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof |
| BR112023022765A2 (en) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | ANTIGEN-BINDING PROTEINS THAT SPECIFICALLY BIND PRAME |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| CN114920823B (en) * | 2022-05-27 | 2023-10-17 | 重庆医科大学 | TCR or antigen binding fragment thereof and uses thereof |
| EP4558152A2 (en) * | 2022-07-22 | 2025-05-28 | Board of Regents, The University of Texas System | Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy |
| CN115850444B (en) * | 2022-09-15 | 2025-01-28 | 重庆医科大学 | TCR or antigen binding fragment thereof and application thereof |
| CN117777270B (en) * | 2022-09-29 | 2025-04-25 | 广州医科大学 | T Cell Receptor (TCR) and application thereof |
| EP4633665A2 (en) * | 2022-12-13 | 2025-10-22 | BioNTech US Inc. | T cell receptor constructs and uses thereof |
| WO2025006196A1 (en) | 2023-06-28 | 2025-01-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
| CN120157754A (en) * | 2023-12-14 | 2025-06-17 | 新景智源生物科技(苏州)有限公司 | KRAS_G12D mutant antigen-specific TCR and its co-expression with CD8 redirects CD4 T cells |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
| US20020150891A1 (en) * | 1994-09-19 | 2002-10-17 | Leroy E. Hood | Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region |
| US7709002B1 (en) | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| AU2003265948B8 (en) | 2002-09-06 | 2009-09-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| AU2008206442B2 (en) | 2007-01-12 | 2012-10-18 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | gp100-specific T cell receptors and related materials and methods of use |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| BR112013006718B1 (en) | 2010-09-20 | 2021-12-07 | Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh | NY-ESO-1 SPECIFIC T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND USE THEREOF |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| PT2755997T (en) * | 2011-09-15 | 2018-10-30 | Us Health | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| WO2013081188A1 (en) * | 2011-11-30 | 2013-06-06 | 独立行政法人国立がん研究センター | Induced malignant stem cells |
| KR20160013049A (en) * | 2013-06-03 | 2016-02-03 | 노파르티스 아게 | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
| GB201313377D0 (en) * | 2013-07-26 | 2013-09-11 | Adaptimmune Ltd | T cell receptors |
| GB201314404D0 (en) * | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| CA2968399A1 (en) | 2014-11-26 | 2016-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mutated kras t cell receptors |
| MX2018003062A (en) | 2015-09-15 | 2018-09-11 | Us Health | T-CELL RECEPTORS RECOGNIZING KRAS MUTANT RESTRICTED IN HLA-CW8. |
| IL264425B2 (en) * | 2016-08-02 | 2023-09-01 | Us Secretary Department Of Health And Human Services | Anti-kras-g12d t cell receptors |
| WO2025006196A1 (en) | 2023-06-28 | 2025-01-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
-
2017
- 2017-07-31 IL IL264425A patent/IL264425B2/en unknown
- 2017-07-31 ES ES17749580T patent/ES2928051T3/en active Active
- 2017-07-31 HR HRP20221183TT patent/HRP20221183T1/en unknown
- 2017-07-31 US US16/321,899 patent/US10611816B2/en active Active
- 2017-07-31 EP EP17749580.1A patent/EP3494133B1/en active Active
- 2017-07-31 SG SG11201900654QA patent/SG11201900654QA/en unknown
- 2017-07-31 SI SI201731231T patent/SI3494133T1/en unknown
- 2017-07-31 PL PL17749580.1T patent/PL3494133T3/en unknown
- 2017-07-31 WO PCT/US2017/044615 patent/WO2018026691A1/en not_active Ceased
- 2017-07-31 SG SG10201913959WA patent/SG10201913959WA/en unknown
- 2017-07-31 HU HUE17749580A patent/HUE060121T2/en unknown
- 2017-07-31 JP JP2019505220A patent/JP6993402B2/en active Active
- 2017-07-31 LT LTEPPCT/US2017/044615T patent/LT3494133T/en unknown
- 2017-07-31 RS RS20220894A patent/RS63615B1/en unknown
- 2017-07-31 SM SM20220379T patent/SMT202200379T1/en unknown
- 2017-07-31 CN CN202410214235.4A patent/CN118063591A/en active Pending
- 2017-07-31 AU AU2017306038A patent/AU2017306038B2/en active Active
- 2017-07-31 PT PT177495801T patent/PT3494133T/en unknown
- 2017-07-31 IL IL301894A patent/IL301894B2/en unknown
- 2017-07-31 CA CA3032870A patent/CA3032870A1/en active Pending
- 2017-07-31 DK DK17749580.1T patent/DK3494133T3/en active
- 2017-07-31 EP EP22182473.3A patent/EP4159751A1/en active Pending
- 2017-07-31 KR KR1020197005837A patent/KR102527052B1/en active Active
- 2017-07-31 CN CN201780059356.4A patent/CN109790211B/en active Active
-
2020
- 2020-04-02 US US16/838,395 patent/US11208456B2/en active Active
-
2021
- 2021-06-11 US US17/345,390 patent/US11897933B2/en active Active
- 2021-12-03 US US17/541,619 patent/US11840561B2/en active Active
- 2021-12-09 JP JP2021199878A patent/JP7413338B2/en active Active
-
2023
- 2023-09-21 AU AU2023233125A patent/AU2023233125B2/en active Active
- 2023-12-27 JP JP2023221526A patent/JP7649370B2/en active Active
-
2024
- 2024-01-25 US US18/423,020 patent/US12391742B2/en active Active
-
2025
- 2025-03-07 JP JP2025036871A patent/JP2025090690A/en active Pending
- 2025-07-15 US US19/269,450 patent/US20250340611A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900654QA (en) | Anti-kras-g12d t cell receptors | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201903089RA (en) | Aav delivery of nucleobase editors | |
| SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201908658TA (en) | Nucleobase editors comprising nucleic acid programmable dna binding proteins | |
| SG11201908784TA (en) | Improved antigen binding receptor formats | |
| SG11201908023YA (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
| SG11201806758VA (en) | Vcn enhancer compositions and methods of using the same | |
| SG11201907754RA (en) | Anti-phf-tau antibodies and uses thereof | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
| SG11201806400XA (en) | Replicative transposon system | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
| SG11201903042VA (en) | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201901790YA (en) | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201806392XA (en) | Personalized delivery vector-based immunotherapy and uses thereof |